SEPNSepterna, Inc.
Is the price fair?
Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~4% a year FCF growth. Moderate growth expectations are priced in.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SEPN's price assumes
Septerna, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 15.2× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 5.6%
Free cash flow yield · Biotechnology median 4.3%
- Growth the price implies
- +4.2%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
- Price / book
- 3.89
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 3.89
- EV / EBIToperating margin −44%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $105M
- Market capitalisation46.7 million shares, counted Aug 5, 2026
- $1.88B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Biotechnology
The closest names by size in the same industry